
Feature|Articles|June 9, 2025
- Vol 53 No 06
- Volume 53
- Issue 06
En bloc resection of bladder tumor: Is it the way forward?
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Advertisement
Advertisement
More than 2 centuries ago, Philipp Bozzini invented the Lichtleiter, allowing urologists to visualize what is inside the bladder.1 About 1 century ago, Maximilian Stern invented the first resectoscope, which allows us to remove a bladder tumor with electrocautery.2 These 2 crucial elements empowered urologists to perform transurethral resection of bladder tumor (TURBT), a highly revolutionary approach given the limited resources that urologists had at that time.
Related to this article

A decision is expected by the fourth quarter of 2026.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

Eugene Cone, MD, discusses the impact of ongoing BCG supply challenges and the potential role of alternative and recombinant strains for NMIBC care.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Advertisement
Advertisement

